retatrutide triple agonist weight loss 🚨 TRIUMPH-1 Phase 3 top-line results, much awaited and just announced ⬇️ 28.3% at 80 weeks ⬇️ 30.3% weight loss at 104 weeks among adults with baseline BMI >35 PCH - Elevate your weight

GLP-1 medications are reducing appetite and portion sizes, raising the nutritional bar for every single bite

Those whose excess weight relates more to metabolic factors than behavioral patterns may see somewhat less dramatic appetite changes but still achieve substantial weight loss through the metabolic pathway effects

Kurnia, Optimal concentration of prebiotic raffinose to increase viability of Lactobacillus acidophilus, Lactobacillus bulgaricus, Streptococcus thermophilus., Carpathian J

Updates 59 , 100796 (2021)

Unraveling a causal relationship between GLP-1 agonists and AP is intricate, particularly as patients with T2DM are already three times more predisposed to pancreatitis compared to their non-diabetic counterparts (Girman et al., 2010)

Beyond weight reduction, these actions can improve metabolic health